Organon & Co.
OGN
Pozycja w akcjach
#4358
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Cena akcji
$13.75
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$3.61B
Zmiana (1 dzień)
-0.11%
Zmiana (1 rok)
48.76%
Kraj
US
Handel Organon & Co. (OGN)
Kategoria
Healthcare
Wskaźnik P/S dla Organon & Co. (OGN)
Wskaźnik P/S na dzień October 2026 TTM: 0.59
Według najnowszych raportów finansowych i ceny akcji Organon & Co., obecny wskaźnik P/S (TTM) wynosi 0.59. Na koniec 2023 wynosił 0.59.
Historia wskaźnika P/S dla Organon & Co. od 2017 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 0.59 | -1.85% |
| 2024 | 0.60 | 1.92% |
| 2023 | 0.59 | -48.87% |
| 2022 | 1.15 | -6.15% |
| 2021 | 1.22 | 17.62% |
| 2020 | 1.04 | -3.79% |
| 2019 | 1.08 | 25.71% |
| 2018 | 0.86 | 7.40% |
| 2017 | 0.80 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 14.32 | 2,331.67% |
US
|
|
| 6.16 | 946.00% |
US
|
|
| 7.78 | 1,221.12% |
US
|
|
| 5.48 | 830.79% |
US
|
|
| 4.66 | 691.02% |
CH
|
